GEMINI-CVR

**GEMINI-CVR** is an investigational preclinical cardiovascular drug program from **Alnylam Pharmaceuticals** built on the company's **GEMINI dual-target RNAi platform**. It is designed as a **single chemical entity** intended to **simultaneously silence two hepatic gene transcripts**, **angiopoietin-like 3** and **angiotensinogen**, with the goal of reducing **atherogenic lipids** and **blood pressure** in patients at high cardiovascular risk. Based on Alnylam's platform description, GEMINI-CVR is best characterized as a **small interfering RNA RNA therapy** for **cardiovascular disease**, although no commercial name, dosage form, route, or specific clinical indication has been publicly established.